Liraglutide - A novel GLP-1 analogue

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 3, Issue 3, 2009, Pages 200-204

  Kalra, Sanjay ^a   Kalra, Bharti ^a   Sharma, Amit ^a  

^a Bharti Hospital and Bharti Research Institute of Diabetes and Endocrinology   (India)

Author keywords

Glucagon like peptide 1 (GLP 1); Incretins; Liraglutide; Type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIN; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; INCRETIN; LIRAGLUTIDE; METFORMIN; NEW DRUG; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHODIESTERASE VII INHIBITOR; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; VILDAGLIPTIN;

CLINICAL TRIAL; CONTINUOUS INFUSION; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATENT; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; WEIGHT REDUCTION;

EID: 70349204370     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221409789104719     Document Type: Review

References (32)

1. UK Prospective Diabetes Study Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. Diabetes 1995; 44(11): 1249-1258.
2. Davis TM, Cull CA, Holman RR. UK Prospective Diabetes Study (UKPDS) Group. Relationship between ethnicity and glycaemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective Diabetes Study (UKPDS 55). Diabetes Care 2001; 24(7): 1167-1174.
3. Jarrett RJ, McCartney P, Keen H. The Bedford survey: Ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics. Diabetologia 1982; 22(2): 79-84.
4. Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26(11): 3080-3086.
5. Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycaemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 7; 355(23): 2427-2443.
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854-865.
7. Ford ES, Li C, Little RR, Mokdad AH. Trends in A1C concentrations among US adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 2008; 31(1): 102-104.
8. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29(1): 46-52.
9. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 1987; 2(8571): 1300-1304.
10. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in Type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86(8): 3717-3723.
11. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 2002; 45(8): 1111-1119.
12. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36(8): 741-744.
13. Larsen J, Hylleberg B, Ng K, Damsbo P. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001; 24(8): 1416-1421.
14. Kieffer TJ, Mcintosh CHS, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136(8): 3585-3596.
15. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45(2): 195-202.
16. Damholt B, Golor G, Wierich W, Pederson P, Ekblom M, Zdravkovic M. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol 2006; 46(6): 635-641.
17. Vilsbøll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008; 25(2): 152-156.
18. Nauck MA, El-Ouaghlidi A, Hompesch M, Jacobsen J, Elbrond B. No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2-diabetes. Diabetes 2008; 52 (Suppl 1): A128.
19. Steensgaard DB, Thomsen JK, Olsen HB, Knudsen LB. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide. Diabetes 2008; 57 (Suppl 1): A164.
20. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003; 52(7): 1786-1791.
21. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43(9): 1664-1669.
22. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53(5): 1187-1194.
23. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analog, added to a sulfonylurea (SU) offers significantly better glycaemic control and favourable weight change compared with rosiglitazone and SU combination therapy in subjects with type 2 diabetes. Diabetes 2008; 57 (Suppl 1): A4.
24. Nauck M, Frid A, Hermansen K, et al. For the LEAD-2 Metformin Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes. Diabetes Care 2009; 32: 84-90.
25. Garber A, Henry R, Ratner R, et al. For the LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride mono-therapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel treatment trial. Lancet 2009; 373 (9962): 473-481.
26. Zinman B, Gerich J, Buse J, et al. Effect of the GLP-1 analog liraglutide on glycaemic control and weight reduction in patients on metformin and rosiglitazone: A randomized double-blind placebo-controlled trial. Can J Diabetes 2008; 32 (Suppl): Abst 107.
27. Russell-Jones D, Vaag A, Schmitz O, et al. Significantly better glycaemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: All as add-on to metformin and a sulfonylurea in type 2 diabetes. Diabetes 2008; 57 (Suppl 1): A159.
28. Brand, S.J., Cruz, A., Pastrak, A., Hew, Y.: US20090036381 (2009).
29. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol 2009; 297: 137-140.
30. Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide significantly improves glycaemic control, and lowers body weight without risk of either major or minor hypoglycaemic episodes in subjects with Type 2 diabetes. Diabetes Care 2007; 30: 1608-1610.
31. Meinke, P. T., Denker, A., Meininger, G.E., Uemura, N., Wagner, J.A., Charnick, S.: WO2008137105(2008).
32. Klein, T., Blaser, A., Rudolph, B., Kautz, U., Selige, J., Kromer, W.: WO2008028914A1(2008).